Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475406 | 1.00 | IDO1 (0.34) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL4570602 | 0.72 | — | — | |
| SCHEMBL28087870 | 0.72 | IDO1 (0.33) | IDO1 | |
| SCHEMBL12264200 | 0.71 | IDO1 (0.39) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL7028419 | 0.67 | IDO1 (0.36) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL7739423 | 0.67 | IDO1 (0.36) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL2931874 | 0.67 | MEN1 (0.36) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL11982524 | 0.67 | IDO1 (0.36) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL7022756 | 0.67 | IDO1 (0.36) | IDO1MEN1CYP1A2BCHEPOLB | |
| SCHEMBL3067264 | 0.67 | IDO1 (0.46) | IDO1MEN1CYP1A2BCHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240261316-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. | 2024-08-08 | — | — | US | disclosed |
| EP-3645548-B1 | METHODS FOR PREPARING BILE ACIDS | MEDYTOX INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-2001513-A1 | THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2008-12-17 | — | — | EP | disclosed |
| EP-1981544-A2 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF | KIST Korea Institute of Science and Technology (KR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007114549-A1 | THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007083875-A2 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-07-26 | — | — | WO | disclosed |
| EP-1052264-B1 | Process for the synthesis of nucleoside analogs | PFIZER PROD INC (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050037413-A1 | functionalized substrates bound to layers of dendrimers and to target-specific ligands, used in combinatorial chemistry, protein, nucleic acid or nucleic acid/peptide hybridization detection; medical diagnosis | POSCO (KR) | 2005-02-17 | — | — | US | disclosed |
| US-6271370-B1 | REACTING 2',3'-O-ALKYLIDENE .BETA.-FURANOSYL HALIDE COMPOUND WITH HETEROCYCLE HAVING RING NITROGEN CAPABLE OF FORMING COVALENT BOND WITH ANOMERIC CARBON OF FURANOSE OR FURANOSE ANALOG IN DIMETHYL SULFOXIDE IN PRESENCE OF STRONG BASE | PFIZER INC | 2001-08-07 | — | — | US | disclosed |
| EP-1052264-A2 | Process for the synthesis of nucleoside analogs | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6060207-A | LOW IN ABSORPTION OF A LIGHT SOURCE OF SHORT WAVELENGTH AND EXCELLENT IN DRY ETCH RESISTANCE; COMPRISES A COMPOUND HAVING A TERPENOID SKELETON | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | IDO1 1250/4885MEN1 4130/4885CYP1A2 1898/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | IDO1 1637/4885MEN1 3189/4885CYP1A2 840/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | IDO1 1250/4885MEN1 4130/4885CYP1A2 1898/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | IDO1 2727/4885MEN1 1145/4885CYP1A2 3256/4885 |
| US-20240261316-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, ACE2, MTAP | IDO1 1250/4885MEN1 4130/4885CYP1A2 1898/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | IDO1 2945/4885MEN1 933/4885CYP1A2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.